// App-Quantinova.ai

: Evaluation of the Long Term Safety and Tolerability of Oral Atogepant 60 Mg Once Daily for Preventive Treatment of Migraine A Phase 3 40 Week Multicenter Extension to the Advance Trial

Researchers

Presenter

  • Brad Klein

Principal Investigators

  • Rosa Miceli

  • Lawrence Severt

  • Peter McAllister

  • Laszlo Mechtler

  • Jennifer McVige

  • Merle Diamond

  • Michael Marmura

  • Hua Guo

  • Michelle Finnegan

  • Joel Trugman

Medical Centers

  • Abington Neurological Associates

  • Abbvie bioresearch Center, Worcester, MA

  • New England Inst for Neurology and Headache

  • Diamond Headache Clinic

  • Thomas Jefferson University, PA

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Migraine

Biomarkers

  • N/A

Drug/Treatment

  • Calcitonin

  • CGRP

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • NCT02848326

  • NCT03777059

  • NCT03939312

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved